| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |